| 56512-7 |
Porphyrins |
MCnt |
Stool |
Pt |
Qn |
|
|
ACTIVE |
Porphyrins [Mass/mass] in Stool |
|
MIN |
DefinitionDescription |
|
|
ug/g |
|
|
|
|
|
|
CHEM |
|
56512-7 |
|
|
|
|
Both |
|
|
|
0 |
Porphyrins Stl-mCnt |
|
|
|
N |
|
Bowel movement; Chemistry; Faecal; Faeces; Fecal; Feces; Hematology; Heme; Mass Content; Point in time; Porph; Porphyrin; QNT; Quan; Quant; Quantitative; Random; Stl; Stool = Fecal |
2.7 |
2.29 |
|
|
|
|
|
|
|
ug/g |
|
|
|
0 |
| 56513-5 |
Hepatitis E virus Ab.IgG |
ACnc |
Ser/Plas |
Pt |
Qn |
IA |
|
ACTIVE |
Hepatitis E virus IgG Ab [Units/volume] in Serum or Plasma by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
56513-5 |
|
IA |
|
|
Both |
|
|
|
0 |
HEV IgG SerPl IA-aCnc |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; EIA; ELFA; ELISA; Enzyme immunoassay; Hep; Hep E; Hepatis; Hepatit; HEV; IAA; ID; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; MEIA; Microbiology; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; SUDS |
2.69 |
2.29 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016.; Updated System from Ser to Ser/Plas. |
0 |
| 56514-3 |
Legionella pneumophila Ab.IgG |
PrThr |
Ser |
Pt |
Ord |
IF |
|
ACTIVE |
Legionella pneumophila IgG Ab [Presence] in Serum by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
56514-3 |
|
IF |
|
|
Both |
|
|
|
0 |
L pneumo IgG Ser Ql IF |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin G; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin G; Infectious Disease; InfectiousDisease; L pneumo; L pneumonphila; Legion; Legionela; Microbiology; Ordinal; Pneu; pneum; Pneumophilia; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR; Time Resolved Fluorescence; TRF |
2.56 |
2.29 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 56515-0 |
Plasmodium falciparum Ab.IgG |
PrThr |
Ser |
Pt |
Ord |
IF |
|
ACTIVE |
Plasmodium falciparum IgG Ab [Presence] in Serum by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
56515-0 |
|
IF |
|
|
Both |
|
|
|
0 |
P falciparum IgG Ser Ql IF |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin G; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin G; Infectious Disease; InfectiousDisease; Malaria; Malarial; Microbiology; Ordinal; P falciparum; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR; Time Resolved Fluorescence; TRF |
2.56 |
2.29 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 56516-8 |
C peptide^6M post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
C peptide [Mass/volume] in Serum or Plasma --6 minutes post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
CHAL |
|
56516-8 |
|
|
|
|
Observation |
|
|
|
0 |
C peptide 6M p chal SerPl-mCnc |
|
|
|
N |
|
6M p chal; After; CHEMISTRY.CHALLENGE TESTING; Connecting peptide of insulin; Level; Mass concentration; p chal; Pept; Pl; Plasma; Plsm; Point in time; Pro-insulin c peptide; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.29 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 56517-6 |
11-Deoxycortisol^2H post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
11-Deoxycortisol [Mass/volume] in Serum or Plasma --2 hours post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ug/dL |
|
|
|
|
|
|
CHAL |
|
56517-6 |
|
|
|
|
Observation |
|
|
|
0 |
11DC 2h p chal SerPl-mCnc |
|
|
|
N |
|
11DC; 120 min; 120 minutes; 120min; 2 hours; 2h p chal; After; CHEMISTRY.CHALLENGE TESTING; Compound S; Cortexolone; Cortodoxone; Deoxycortisol; Desoxycortisol; Level; Mass concentration; Metopirone; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.4 |
2.29 |
|
|
|
|
|
|
|
ug/dL |
|
|
|
0 |
| 56518-4 |
11-Deoxycortisol^15M post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
11-Deoxycortisol [Mass/volume] in Serum or Plasma --15 minutes post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
CHAL |
|
56518-4 |
|
|
|
|
Observation |
|
|
|
0 |
11DC 15M p chal SerPl-mCnc |
|
|
|
N |
|
11DC; 15M p chal; After; CHEMISTRY.CHALLENGE TESTING; Compound S; Cortexolone; Cortodoxone; Deoxycortisol; Desoxycortisol; Level; Mass concentration; Metopirone; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.29 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
| 56519-2 |
11-Deoxycortisol^30M post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
11-Deoxycortisol [Mass/volume] in Serum or Plasma --30 minutes post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
CHAL |
|
56519-2 |
|
|
|
|
Observation |
|
|
|
0 |
11DC 30M p chal SerPl-mCnc |
|
|
|
N |
|
11DC; 30M p chal; After; CHEMISTRY.CHALLENGE TESTING; Compound S; Cortexolone; Cortodoxone; Deoxycortisol; Desoxycortisol; Level; Mass concentration; Metopirone; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.29 |
|
|
|
|
|
|
|
ug/dL |
|
|
|
0 |
| 5652-3 |
Formaldehyde |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Formaldehyde [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
mg/L |
|
|
|
|
|
|
DRUG/TOX |
|
5652-3 |
|
|
|
|
Both |
|
|
|
0 |
Formaldehyde Bld-mCnc |
|
|
|
Y |
|
Blood; DRUG/TOXICOLOGY; Drugs; Formalin; k80; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.42 |
1 |
|
|
|
|
|
|
|
mg/L |
|
|
|
0 |
| 56520-0 |
11-Deoxycortisol^45M post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
11-Deoxycortisol [Mass/volume] in Serum or Plasma --45 minutes post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
CHAL |
|
56520-0 |
|
|
|
|
Observation |
|
|
|
0 |
11DC 45M p chal SerPl-mCnc |
|
|
|
N |
|
11DC; 45M p chal; After; CHEMISTRY.CHALLENGE TESTING; Compound S; Cortexolone; Cortodoxone; Deoxycortisol; Desoxycortisol; Level; Mass concentration; Metopirone; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.29 |
|
|
|
|
|
|
|
ug/dL |
|
|
|
0 |
| 56521-8 |
11-Deoxycortisol^1.5H post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
11-Deoxycortisol [Mass/volume] in Serum or Plasma --1.5 hours post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
CHAL |
|
56521-8 |
|
|
|
|
Observation |
|
|
|
0 |
11DC 1.5h p chal SerPl-mCnc |
|
|
|
N |
|
1 1/2 hours; 1 1/2 HR; 1.5h p chal; 1.5Hr; 11DC; 90 min; 90 minutes; 90M; 90min; After; CHEMISTRY.CHALLENGE TESTING; Compound S; Cortexolone; Cortodoxone; Deoxycortisol; Desoxycortisol; Level; Mass concentration; Metopirone; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.29 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
| 56522-6 |
17-Hydroxypregnenolone^30M post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
17-Hydroxypregnenolone [Mass/volume] in Serum or Plasma --30 minutes post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
56522-6 |
|
|
|
|
Observation |
|
|
|
0 |
17OH-Preg 30M p chal SerPl-mCnc |
|
|
|
N |
|
17 alpha-Hydroxypregnanolone; 17 hydroxy pregnenolone; 17-alpha-Hydroxypregnenolone; 17alpha-Hydroxypregnenolone; 17OH-Preg; 30M p chal; After; CHEMISTRY.CHALLENGE TESTING; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
2.32 |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |
| 56523-4 |
Insulin-like growth factor-I^15M post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Insulin-like growth factor-I [Mass/volume] in Serum or Plasma --15 minutes post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ug/L |
|
|
|
|
|
|
CHAL |
|
56523-4 |
|
|
|
|
Observation |
|
|
|
0 |
IGF-I 15M p chal SerPl-mCnc |
|
|
|
N |
|
15M p chal; After; CHEMISTRY.CHALLENGE TESTING; Fac; Fact; Factor 1; FI; HUM; Humulin; IGF; IGF1; IGF-1; IGF-I; IH7; Insul; Lente; Level; Mass concentration; NPH; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Semilente; SerP; SerPl; SerPlas; Serum; Serum or plasma; Sliding; Somatomedin C; SR; Ultralente |
2.7 |
2.29 |
|
|
|
|
|
|
|
ug/L |
|
|
|
0 |
| 56524-2 |
Insulin-like growth factor-I^45M post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Insulin-like growth factor-I [Mass/volume] in Serum or Plasma --45 minutes post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ug/L |
|
|
|
|
|
|
CHAL |
|
56524-2 |
|
|
|
|
Observation |
|
|
|
0 |
IGF-I 45M p chal SerPl-mCnc |
|
|
|
N |
|
45M p chal; After; CHEMISTRY.CHALLENGE TESTING; Fac; Fact; Factor 1; FI; HUM; Humulin; IGF; IGF1; IGF-1; IGF-I; IH7; Insul; Lente; Level; Mass concentration; NPH; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Semilente; SerP; SerPl; SerPlas; Serum; Serum or plasma; Sliding; Somatomedin C; SR; Ultralente |
2.34 |
2.29 |
|
|
|
|
|
|
|
ug/L |
|
|
|
0 |
| 56525-9 |
5-Hydroxytryptophan |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
5-Hydroxytryptophan [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
mg/L |
|
|
|
|
|
|
DRUG/TOX |
|
56525-9 |
|
|
|
|
Both |
|
|
|
0 |
5OH-Tryptophan Ur-mCnc |
|
|
|
N |
|
5-HTP; 5-Hydroxy tryptophan; 5OH-Tryptophan; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.7 |
2.29 |
|
|
|
|
|
|
|
mg/L |
|
|
|
0 |
| 56526-7 |
Somatotropin^30M post exercise |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Somatotropin [Mass/volume] in Serum or Plasma --30 minutes post exercise |
|
MIN |
DefinitionDescription |
|
|
ug/L;ng/mL |
|
|
|
|
|
|
CHAL |
|
56526-7 |
|
|
|
|
Observation |
|
|
|
0 |
GH 30M p Exc SerPl-mCnc |
|
|
|
N |
|
30M p Exc; After; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; EXCZ; GH; Growth hormone; HGH; Human growth hormone; Level; Mass concentration; p Exc; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Somatotropic hormone; SR; STH |
2.7 |
2.29 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 56527-5 |
Vasopressin^1H post XXX challenge |
MCnc |
Plas |
Pt |
Qn |
|
|
ACTIVE |
Vasopressin [Mass/volume] in Plasma --1 hour post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
pg/mL |
|
|
|
|
|
|
CHAL |
|
56527-5 |
|
|
|
|
Observation |
|
|
|
0 |
Vasopressin 1h p chal Plas-mCnc |
|
|
|
N |
|
1 hour; 1.0Hr; 1h p chal; 60 min; 60 minutes; 60M; 60min; ADH; Adiuretin; After; Antidiuretic hormone; Arginine vasopressin hormone; AVH; CHEMISTRY.CHALLENGE TESTING; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; VP |
2.42 |
2.29 |
|
|
|
|
|
|
|
pg/mL |
|
|
|
0 |
| 56528-3 |
Androstenedione^20M post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Androstenedione [Mass/volume] in Serum or Plasma --20 minutes post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
56528-3 |
|
|
|
|
Observation |
|
|
|
0 |
Androst 20M p chal SerPl-mCnc |
|
|
|
N |
|
20M p chal; After; CHEMISTRY.CHALLENGE TESTING; gamma-4-Androstenedione; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.29 |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |
| 56529-1 |
Ma+Ta Ab |
Titr |
CSF |
Pt |
SemiQn |
IF |
|
ACTIVE |
Ma+Ta Ab [Titer] in Cerebral spinal fluid by Immunofluorescence |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
SERO |
|
56529-1 |
|
IF |
|
|
Both |
|
|
|
0 |
Ma+Ta Ab Titr CSF IF |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; Cerebral spinal fluid; Cerebrospinal Fl; Dilution factor; Dilution Factor (Titer); FA; Fluorescent antibody; Fluoresent; IFA; Immune fluorescence; Immunoflour; Immunofluor; Immunofluorescence; MA1; MA-1; Ma2; MATA; Paraneoplastic Ag Ma 1; Paraneoplastic syndrome; PNMA1; Point in time; Random; Serology; SmQn; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Time Resolved Fluorescence; Titer; Titered; Titre; TRF; Ttr |
2.75 |
2.29 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 5653-1 |
Formaldehyde |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Formaldehyde [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
mg/L |
|
|
|
|
|
|
DRUG/TOX |
|
5653-1 |
|
|
|
|
Both |
|
|
|
0 |
Formaldehyde Ur-mCnc |
|
|
|
Y |
|
DRUG/TOXICOLOGY; Drugs; Formalin; k80; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.42 |
1 |
|
|
|
|
|
|
|
mg/L |
|
|
|
0 |
| 56530-9 |
CV2 Ab |
Titr |
CSF |
Pt |
SemiQn |
IF |
|
ACTIVE |
CV2 Ab [Titer] in Cerebral spinal fluid by Immunofluorescence |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
SERO |
|
56530-9 |
|
IF |
|
|
Both |
|
|
|
0 |
CV2 Ab Titr CSF IF |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; Cerebral spinal fluid; Cerebrospinal Fl; Collapsin response mediator protein 5; Collapsin response mediator protein 5 Ab; CRMP5; CRMP-5; Dilution factor; Dilution Factor (Titer); FA; Fluorescent antibody; Fluoresent; IFA; Immune fluorescence; Immunoflour; Immunofluor; Immunofluorescence; Neuro; Neurology; Point in time; POP66; Random; Serology; SmQn; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Time Resolved Fluorescence; Titer; Titered; Titre; TRF; Ttr; ULIP |
2.75 |
2.29 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 56531-7 |
Amphiphysin Ab |
Titr |
CSF |
Pt |
SemiQn |
IF |
|
ACTIVE |
Amphiphysin Ab [Titer] in Cerebral spinal fluid by Immunofluorescence |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
SERO |
|
56531-7 |
|
IF |
|
|
Both |
|
|
|
0 |
Amphiphysin Ab Titr CSF IF |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; breast cancer; Cerebral spinal fluid; Cerebrospinal Fl; Dilution factor; Dilution Factor (Titer); FA; Fluorescent antibody; Fluoresent; IFA; Immune fluorescence; Immunoflour; Immunofluor; Immunofluorescence; Neuro; Neurology; Paraneoplastic syndrome; Point in time; Random; Serology; SmQn; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Stiff Man Syndrome; Time Resolved Fluorescence; Titer; Titered; Titre; TRF; Ttr |
2.75 |
2.29 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 56532-5 |
Asialoglycoprotein receptor Ab |
ACnc |
Ser |
Pt |
Qn |
IA |
|
ACTIVE |
Asialoglycoprotein receptor Ab [Units/volume] in Serum by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
56532-5 |
|
IA |
|
|
Both |
|
|
|
0 |
ASGPR Ab Ser IA-aCnc |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; ASGPR; Autoantibodies; Autoantibody; EIA; ELFA; ELISA; Enzyme immunoassay; Hepatology; IAA; Liver; MEIA; Point in time; QNT; Quan; Quant; Quantitative; Random; Rec; Recept; Receptors; Recp; Recptr; Serology; Serum; SR; SUDS |
2.69 |
2.29 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 56533-3 |
Insulin Ab.IgG |
ACnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Insulin IgG Ab [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
56533-3 |
|
|
|
|
Both |
|
|
|
0 |
Insulin IgG Ser-aCnc |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; Endocrine; Endocrinology; HUM; Humulin; IH7; Immune globulin G; Immunoglobulin G; Insul; Lente; NPH; Point in time; QNT; Quan; Quant; Quantitative; Random; Semilente; Serology; Serum; Sliding; SR; Ultralente |
2.73 |
2.29 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 56534-1 |
Calcitonin^15M post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Calcitonin [Mass/volume] in Serum or Plasma --15 minutes post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
pg/mL |
|
|
|
|
|
|
CHAL |
|
56534-1 |
|
|
|
|
Observation |
|
|
|
0 |
Calcit 15M p chal SerPl-mCnc |
|
|
|
N |
|
15M p chal; After; CHEMISTRY.CHALLENGE TESTING; CT; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Thyrocalcitonin; Tumor marker |
2.7 |
2.29 |
|
|
|
|
|
|
|
pg/mL |
|
|
|
0 |
